Studies evaluating the combination of PD-1/PD-L1 inhibitors with standard chemotherapy or anti-angiogenic agents have demonstrated significant improvements in progression-free and overall survival among advanced CRC patients 5-7. The gene discussed is CD274; the disease is colorectal carcinoma.